Regencell Bioscience Holdings Limited
RGC
$-0.35
Change (1 day)
$32.44
Year High
$3.03
Year Low
Categories
Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
Earnings for Regencell Bioscience Holdings Limited (RGC)
Earnings in 2023 (TTM): $-6,062,329
According to Regencell Bioscience Holdings Limited's latest financial reports the company's current earnings (TTM) are $-6,062,329. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Regencell Bioscience Holdings Limited
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-6,062,329 | $-5,871,130 |
| 2022 | $-7,594,555 | $-7,422,728 |
| 2021 | $-1,346,745 | $-1,346,745 |
| 2020 | $-812,371 | $-812,371 |
| 2019 | $-390,990 | $-390,990 |
| 2018 | $213.9 M | $112.3 M |
| 2017 | $281.7 M | $170.4 M |
| 2016 | $253.3 M | $153.4 M |
| 2015 | $178.6 M | $105.6 M |
| 2013 | $264.6 M | $157.7 M |
| 2012 | $235.9 M | $144.8 M |
| 2011 | $75.7 M | $77.6 M |
| 2010 | $157.2 M | $95.5 M |
| 2009 | $123 M | $72 M |
| 2007 | $605 M | $363 M |
| 2006 | $144 M | $86 M |
| 2005 | $142 M | $82 M |
| 2004 | $306 M | $185 M |
| 2002 | $208 M | $117 M |